Avience Biomedicals IPO Details
Avience Biomedicals IPO Summary
Avience Biomedicals IPO opens for subscription on 18 Jun 2026 and closes on 22 Jun 2026.The IPO will be listed on NSE with the tentative listing date set for 25 Jun 2026.
Avience Biomedicals IPO price band has been fixed at ₹196 – ₹208 per share. The face value is ₹10 per share with a lot size of 600.
Avience Biomedicals IPO total issue size comprises 14,53,800 shares (aggregating up to ₹30.24 Cr). This includes a fresh issue of 14,53,800 shares (aggregating up to ₹30.24 Cr). Pre-issue shareholding stands at 40,31,256, which will increase to 54,85,056 post-issue.
Avience Biomedicals IPO carries a ₹145 (69.71%) GMP, reflecting investor sentiment.
Avience Biomedicals IPO Lot Size :Individual Minimum is 2 lots (1,200 shares) amounting to ₹249,600. Individual Maximum is 2 lots (1,200 shares) amounting to ₹249,600. SHNI Minimum is 3 lots (1,800 shares) amounting to ₹374,400. SHNI Maximum is 8 lots (4,800 shares) amounting to ₹998,400. BHNI Minimum is 9 lots (5,400 shares) amounting to ₹1,123,200.
Avience Biomedicals IPO Details
Avience Biomedicals IPO Subscription
Avience Biomedicals IPO Application Wise Breakup
Avience Biomedicals IPO Dates
- 18 Jun 2026Opening dateOpen
- 22 Jun 2026Closing dateClose
- 23 Jun 2026Allotment Date Allotment
- 24 Jun 2026Initiation of RefundsRefund
- 24 Jun 2026Credit of SharesCredit
- 25 Jun 2026Listing dateListing
Avience Biomedicals IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 1200 | ₹249,600 |
| Individual Maximum | 2 | 1200 | ₹249,600 |
| SHNI Minimum | 3 | 1800 | ₹374,400 |
| SHNI Maximum | 8 | 4800 | ₹998,400 |
| BHNI Minimum | 9 | 5400 | ₹1,123,200 |
Avience Biomedicals IPO Reservation
Promoter Holding
Documents
Avience Biomedicals IPO Valuations
Avience Biomedicals Financial Information
| Period Ended | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 51.96 | 43.60 | 25.63 | 10.02 |
| Total Income | 28.85 | 29.54 | 16.64 | 10.93 |
| Profit After Tax | 4.18 | 5.14 | 1.98 | 0.71 |
| EBITDA | 7.10 | 7.65 | 3.15 | 1.43 |
| NET Worth | 24.70 | 20.52 | 6.05 | 4.07 |
| Reserves and Surplus | 20.67 | 16.49 | 2.77 | 0.79 |
| Total Borrowing | 17.17 | 13.75 | 7.73 | 2.66 |
| Amount in ₹ Crore | ||||
About Avience Biomedicals IPO
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.
Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.
The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.
In addition to manufacturing, the Company also act as distributors and traders of medical equipment.
The company's manufacturing unit is situated in Noida, Uttar Pradesh.
The company offers a comprehensive range of diagnostic solutions, including:
- Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test.
- Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit.
- Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY.
- Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer.
- Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM).
As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees
Strength Of Avience Biomedicals IPO
- Experienced Management Team and trained Employees.
- Optimal Utilization of Resources.
- Quality assurance and control.
- Cordial relationships with our clients.
Risk Of Avience Biomedicals IPO
- The pharmaceutical market is subject to extensive regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose us to litigation or other liabilities, which could adversely affect our reputation, business, financial condition and results of operations.
- We are dependent on certain customers for a portion of our revenues. The loss of any of our major customers due to any adverse development or significant reduction in business from our major customers may adversely affect our business, financial condition, results of operations and future prospects.
- We rely on suppliers for medical devices and equipment manufacturers for our trading goods, and also face risks in sourcing raw materials and components from third parties for the manufacturing and assembly of our medical equipment. Any disruption in the supply of these goods or materials could adversely impact our business, operations, and financial condition.
- Our Financial Statement as Restated are prepared and signed by the Peer Review Auditor who is not Statutory Auditors of our Company as required under the provisions of ICDR.
- Our business derives a significant portion of its revenue from the trading sector, and any potential instability in this area could pose a risk to our overall performance.
- The purchase and sale of medical devices and equipment for our trading activities are significantly dependent on related parties.
- Customer orders may experience delays, modifications, cancellations, or may not be fully paid, which could negatively impact our business, financial condition, and operational results.
- We require sizeable amounts of working capital for our continued operation and growth. Our inability to meet our working capital requirements could have a material adverse effect on our business, results of operations and financial condition.
- Our business depends on the efficient functioning of our manufacturing facilities and assembly units. Although we have not received any product-related complaints, occasional machinery breakdowns in the past highlight the importance of regular maintenance and operational enhancements. Any unforeseen obsolescence, damage, theft, or delays in repair could have an adverse impact on our operations, cash flows, financial condition, and results.
- We import a portion of our raw material supply from China. Restrictions on or import duties relating to materials and equipment imported for our manufacturing operations as well as restrictions on or import duties levied on our products in our export markets may adversely affect our business prospects, financial performance and cash flows.
Objectives Avience Biomedicals IPO
1. Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
2. Funding the working capital requirement of the company
3. General Corporate Purposes
Company Contact Details
Avience Biomedicals Ltd.
C-11, Block-C
Community Centre,
Janakpuri A-3,
Delhi, New Delhi, 110058
Phone: 1800-12-04-636
Email: info@avienbio.com
Website: https://avienbio.com/
Registrar Contact Details
Avience Biomedicals FAQs
The Avience Biomedicals IPO is a SME public issue comprising 1453800 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹30.24 Cr. The issue price has been fixed at ₹208 per equity share, and the minimum application size is 600 shares.
The IPO opens for subscription on 18 Jun 2026, and closes on 22 Jun 2026.
Skyline Financial Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the NSE
As of now, the current GMP stands at ₹145 (69.71%).
Quick Links
Comments
